Second Edition

• The Malaysian Guidelines for the Reporting & Monitoring 2002 has been updated to align with current international requirements in adverse drug reaction (ADR) reporting and safety monitoring for medicinal products.
• In addition, this guideline has been updated to explain in detail on ADR reporting for Healthcare Professionals and Product Registration Holders.
• This guideline will be implemented with immediate effect.

(Refer letter to Product Registration Holders, Ruj.Kami: (73)dlm.BPFK/17/FV/4 JILID51, Date: 5 September 2016)